GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.

Rhea-AI Summary

GlobeStar Therapeutics Corporation (OTC PINK:GSTC) announced significant progress in negotiations with a major medical center in the Northeast, moving closer to initiating clinical trials for a new drug targeting Multiple Sclerosis and other neurodegenerative diseases. This advancement underscores their commitment to developing effective healthcare solutions for over 4 million annual diagnoses in the U.S. The team is dedicated to presenting their patented drug to the FDA for approval, reflecting a proactive approach to tackling life-altering conditions.

Positive

• Negotiations with a major Northeast medical center for clinical trials.
• Potential FDA submission for innovative drug targeting Multiple Sclerosis.
• Addressing a significant health issue affecting over 4 million in the U.S. annually.

Negative

• None.

Company has made progress with a major medical center in the Northeast and identified a path forward for this pharmaceutical.

RICHLAND, WA / ACCESSWIRE / October 4, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (www.globestarthera.com), headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease. With a mission to "help people begin their journeys to health," GlobeStar Therapeutics also brings high quality supplement products to the market.

"Our latest filing clearly demonstrates that we are moving forward and are in negotiations with a major hospital in the Northeast region to begin our own clinical trials in the United States," said James C. Katzaroff, President and CEO, GlobeStar Therapeutics Corporation. "This filing shows we are one step closer to presenting this drug to the FDA for approval. The entire GlobeStar Therapeutics team understands the importance of meeting the challenges associated with Multiple Sclerosis and other life-changing neurodegenerative diseases."

Today's document identifies our progress and clearly validates why GlobeStar believes this is an opportunity-rich environment for drug development. GlobeStar's patented solution has the potential to change the lives of millions of patients across the globe. In the United States alone, over 4 million people are diagnosed each year with this life-changing neurodegenerative disease.

GlobeStar Therapeutics Corporation.
GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is a healthcare company dedicated to bringing innovative, effective and high-quality healthcare solutions to the medical community. With a focus on Multiple Sclerosis and other chronic diseases, GlobeStar's team is committed to helping those suffering begin their journey back to health. More information about GlobeStar Therapeutics Corporation can be found at www.globestarthera.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Media Contact:
Brooke Greenwald
Cornerstone Communications, LTD
Brooke@cornerstonepr.net
240-360-0866

SOURCE: AngioSoma, Inc.

View source version on accesswire.com:
https://www.accesswire.com/666590/GlobeStar-Therapeutics-Corporation-Additional-Progress-Toward-A-US-Based-Clinical-Trial

FAQ

What progress has GlobeStar Therapeutics made regarding clinical trials?

GlobeStar Therapeutics is in negotiations with a major medical center in the Northeast to begin clinical trials for its drug targeting Multiple Sclerosis.

What is the significance of GlobeStar's new drug?

The drug aims to address Multiple Sclerosis, a neurodegenerative disease affecting over 4 million people annually in the U.S., with potential life-changing impacts for patients.

When does GlobeStar Therapeutics plan to present its drug to the FDA?

GlobeStar Therapeutics is working towards presenting its patented drug to the FDA for approval as part of their clinical trial process.

What are the next steps for GlobeStar Therapeutics after this press release?

The company aims to finalize negotiations for clinical trials and proceed with their drug development towards FDA submission.